STAT Plus: Pharmalittle: Female CEOs in biotech are still rare; Arizona sues Sacklers in Supreme Court
Rise and shine, everyone, another busy day is on the way. The pace has already picked up, as we watch one of the short people dash out the door to the summer job and our official mascot scoots to the nearest corner for a morning nap. As for us, we are busy doing the usual — brewing cups of stimulation (hot buttered rum is our choice today) and foraging for items of interest. Speaking of which, here are a few tidbits to light a spark under you. Hope your day goes well and you conquer the world. And of course, do keep in touch. …
Female chief executives remain exceedingly rare in the drug industry, accounting for less than 10% of biotech’s top leaders, according to BioPharma Dive. Of 180 leading biotechs, just 15 were led by women last year. Two years ago, the BIO trade group set goals for the industry to reach 50% female representation among management and 30% representation on company boards by 2025. No goal was set for the percentage of female chief executives. The top ranks of the industry remain a ways off from those targets.
Continue to STAT Plus to read the full story…
